CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy

Mario L. Marques-Piubelli; Do Hwan Kim; L. Jeffrey Medeiros; Wei Lu; Khaja Khan; Lorena Isabel Gomez-Bolanos; Saxon Rodriguez; Edwin R. Parra; Chi Young Ok; Akanksha Aradhya; Luisa M. Solis; Yago L. Nieto; Raphael Steiner; Sairah Ahmed; Francisco Vega

doi:10.1111/his.14910

CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy

Mario L. Marques-Piubelli, Do Hwan Kim, L. Jeffrey Medeiros, Wei Lu, Khaja Khan, Lorena Isabel Gomez-Bolanos, Saxon Rodriguez, Edwin R. Parra, Chi Young Ok, Akanksha Aradhya, Luisa M. Solis, Yago L. Nieto, Raphael Steiner, Sairah Ahmed, Francisco Vega

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.

Original language	English (US)
Pages (from-to)	143-148
Number of pages	6
Journal	Histopathology
Volume	83
Issue number	1
DOIs	https://doi.org/10.1111/his.14910
State	Published - Jul 2023

Keywords

CAR T-cell
CD30
classic Hodgkin lymphoma

ASJC Scopus subject areas

Pathology and Forensic Medicine
Histology

Access to Document

10.1111/his.14910

Cite this

Marques-Piubelli, M. L., Kim, D. H., Medeiros, L. J., Lu, W., Khan, K., Gomez-Bolanos, L. I., Rodriguez, S., Parra, E. R., Ok, C. Y., Aradhya, A., Solis, L. M., Nieto, Y. L., Steiner, R., Ahmed, S., & Vega, F. (2023). CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology, 83(1), 143-148. https://doi.org/10.1111/his.14910

Marques-Piubelli, ML, Kim, DH, Medeiros, LJ , Lu, W, Khan, K, Gomez-Bolanos, LI, Rodriguez, S, Parra, ER , Ok, CY, Aradhya, A, Solis, LM , Nieto, YL, Steiner, R, Ahmed, S & Vega, F 2023, 'CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy', Histopathology, vol. 83, no. 1, pp. 143-148. https://doi.org/10.1111/his.14910

@article{bcd321178a7a403595443699dc6c5540,

title = "CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy",

abstract = "Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.",

keywords = "CAR T-cell, CD30, classic Hodgkin lymphoma",

author = "Marques-Piubelli, {Mario L.} and Kim, {Do Hwan} and Medeiros, {L. Jeffrey} and Wei Lu and Khaja Khan and Gomez-Bolanos, {Lorena Isabel} and Saxon Rodriguez and Parra, {Edwin R.} and Ok, {Chi Young} and Akanksha Aradhya and Solis, {Luisa M.} and Nieto, {Yago L.} and Raphael Steiner and Sairah Ahmed and Francisco Vega",

note = "Publisher Copyright: {\textcopyright} 2023 John Wiley & Sons Ltd.",

year = "2023",

month = jul,

doi = "10.1111/his.14910",

language = "English (US)",

volume = "83",

pages = "143--148",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy

AU - Marques-Piubelli, Mario L.

AU - Kim, Do Hwan

AU - Medeiros, L. Jeffrey

AU - Lu, Wei

AU - Khan, Khaja

AU - Gomez-Bolanos, Lorena Isabel

AU - Rodriguez, Saxon

AU - Parra, Edwin R.

AU - Ok, Chi Young

AU - Aradhya, Akanksha

AU - Solis, Luisa M.

AU - Nieto, Yago L.

AU - Steiner, Raphael

AU - Ahmed, Sairah

AU - Vega, Francisco

PY - 2023/7

Y1 - 2023/7

N2 - Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.

AB - Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.

KW - CAR T-cell

KW - CD30

KW - classic Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85151389807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151389807&partnerID=8YFLogxK

U2 - 10.1111/his.14910

DO - 10.1111/his.14910

M3 - Article

C2 - 36994939

AN - SCOPUS:85151389807

SN - 0309-0167

VL - 83

SP - 143

EP - 148

JO - Histopathology

JF - Histopathology

IS - 1

ER -

CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this